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Short Communication
Potent Inhibition of SARS-Associated Coronavirus (SCoV)
Infection and Replication by Type I Interferons (IFN-/) 
but Not by Type II Interferon (IFN-)
BOJIAN ZHENG,1,* MING-LIANG HE,2,* KING-LING WONG,1 CHING TUNG LUM,2 LEO L.M. POON,1
YING PENG,2 YI GUAN,1 MARIE C.M. LIN,2 and HSIANG-FU KUNG2
ABSTRACT
We sought to investigate the anti-severe acute respiratory syndrome (SARS)-associated coronavirus (SCoV)
activities of type I ( and ) and type II () interferons (IFN) in vitro. Type I IFNs protected cells from cy-
topathic effects (CPE) induced by SCoV, and inhibited viral genomic RNA replication in FRhk-4 cells (mea-
sured by quantitative RT-PCR) in a dose-dependent manner. Intracellular viral RNA copies were reduced
50% by IFN- at a concentration of 25 U/ml and by IFN- at a concentration of 14 U/ml. IFN- had fewer
effects on inhibition of viral infection and replication. The type I IFN receptor signaling pathway in host cells
is mainly involved in the inhibition of SCoV infection and replication. Type I IFNs could be used as potential
agents for anti-SARS treatment.
ANOVEL CORONAVIRUS (SCoV) has been identified as thecausative agent of the recent worldwide outbreak of severe
acute respiratory syndrome (SARS).(1,2) Coronaviruses are pos-
itive-stranded RNA viruses with the largest known viral RNA
genomes. SARS remains a threat to public health worldwide,
as it may cross-transmit from animal to human. Interferons
(IFNs) exhibit potent antiviral activities, and, therefore, they are
in regular use for antiviral therapy. IFNs transmit signals to the
cell via the receptor complex to induce an antiviral response.
The binding affinities and the biologic activities among IFN
species are different. The type I (,) and the type II () IFNs
transmit their signals through different receptors.(3–5) There are
several hundred genes transcriptionally regulated by IFNs in re-
sponse to viral invasion. IFN-, and not IFN- or IFN-, was
reported to exhibit potent anti-SCoV activity in Vero and Caco2
cells challenged with a low dose of SCoV (multiplicity of in-
fection [moi] 0.01).(6) In this study, we investigated the effect
of the type I and type II IFNs on inhibition of SCoV infection
and replication in FRhk-4 cells challenged with high doses of
SCoV (moi 0.05) by measuring the viral genomic RNA copies
by quantitative RT-PCR and the viral titers by back-titration.
IFNs  (recombinant IFN-2a) was a gift from Dr. Bill Clark
(PBL Co., Piscataway, NJ). IFN- (recombinant IFN-) and
IFN- (recombinant IFN-) were purchased from Sigma Chem-
ical Co. (St. Louis, MO). The biologic activities (units) of the
IFNs were determined by inhibition of cytopathic effects (CPE)
in Vero cells challenged in the antivesicular stomatitus virus
(VSV) assay. To evaluate the anti-SCoV activity of IFNs, fe-
tal rhesus monkey kidney cells (FRhk-4, purchased from
ATCC, Rockville, MD) in MEM medium supplemented with
10% fetal bovine serum (FBS) were seeded into 96-well plates
(3  103 cells per well) and cultured overnight. Cells were in-
cubated for 1 h with various concentrations of different IFNs
dissolved in 100 l MEM medium, then infected with SCoV
(moi 0.05) diluted in MEM with 1% FBS. Thirty-six hours af-
ter infection with SCoV, the degree of protection against SCoV
viral CPE was determined by observing cell morphology under
a phase-contrast microscope. Total cellular RNA was extracted
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from cells using QIAamp Virus RNA Mini Kit (Qiagen, Hilden,
Germany) as instructed by the manufacturer and was reverse-
transcribed using SuperScript (Invitrogen, San Diego CA). The
FastStart DNA Master SYBR Green I fluorescence reaction
(Roche, Mannheim, Germany) (forward primer 5-TACA-
CACCTCAGCGTTG-3; reverse primer 5-CACGAACGT-
GACGAAT-3) was used in the quantitative PCR assay.(6) Plas-
mids containing the target sequence were used as positive
controls. The viral titers were measured by back-titration ac-
cording to standard protocols.
IFN- and IFN- protected cells from viral CPE. Preincu-
bation for 1 h with 128 U/well IFN- (Fig. 1A, top) and IFN-
 (Fig 1A, bottom) protected cells almost completely. The cell
morphology was indistinguishable from that of normal, unin-
fected cells. Marked protection was visible at concentrations as
low as 16 U/ml IFN- and IFN- (Fig. 1B, C). However, only
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FIG. 1. Inhibition of SCoV-mediated CPE and intracellular viral RNA accumulation by IFNs. The FRhk-4 cells were pretreated
with various concentrations of different IFNs as indicated for 1 h and infected with SCoV. (A) CPE under phase-contrast mi-
croscopy. 400. (Top) IFN- treated. (Bottom) IFN- treated. Real-time RT-PCR was employed to quantify the viral RNA of
SCoV after the cells were treated with IFN and challenged with SCoV. (B and C) Reduction of intracellular viral RNA copies.
weak protection was observed using IFN- at a concentration
of 1000 U/ml (data not shown). To further quantify the effects
of IFNs on inhibition of SCoV infection and replication in
FRhk-4 cells, we measured SCoV intracellular viral RNA
copies by quantitative real-time PCR using total cellular RNA
as the template and viral titer by back-titration.(6,7) Our results
showed that both IFN- and IFN- dose-dependently reduced
SCoV viral RNA copies in cells and infectious titers in the con-
ditioned medium. Approximately 50% reduction of intracellu-
lar viral RNA and viral titers was observed at IFN- and IFN-
 concentrations as low as 25 U/ml and 10 U/ml respectively,
and 90% elimination of viral RNA or 98% of viral titers was
seen at about 3000 U/ml and 1800 U/ml, respectively. IFN-
did not exhibit significant antiviral activity. These results were,
in general, consistent with the results conducted on Caco-2
cells,(7) although the concentrations of IFNs were miscalcu-
lated.(8)
Our results indicate that type I IFNs are much more effec-
tive in inhibiting SCoV infection and replication than are type
II IFNs. There is a wide variety of type I IFN subspecies, each
of which may have different antiviral activities and specifici-
ties.(3–5) For example, Cinatl et al.(7) reported that only IFN-
exhibited potent anti-SCoV activity in Vero cells and Caco2
cells. In fact, it has been show that pegylated IFN- protected
type 1 pneumocytes against SCoV in infection in macaques.(9)
It will be important to identify the most potent IFN subspecies
and conduct preclinical and clinical trials, as SARS is recurring
in China.
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